Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Desmond Tutu HIV Centre
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Clinical Care Options (CCO) commentary by Dr Zhao Yan on data presented at CROI 2021 on the impact of the COVID-19 pandemic on HIV treatment
Clinical Care Options (CCO) commentary by Nelly Mugo, MD, on new data from Kenya on STI incidence and on PrEP uptake from CROI 2021
Expert commentary from CCO detailing the use of HIV-ASSIST to support ART selection in a socially- and medically-complex, treatment-experienced patient with HIV
CCO expert commentary by Dr Monica Gandhi on key considerations with long-acting pre-exposure prophylaxis based on data presented at CROI 2021